It was found that RTP4, SERTAD2, and SP110 were significantly expressed in all pancreatic cancer cells, including those of pancreatic ductal carcinoma, pancreatic adenocarcinoma and metastatic carcinoma, providing a reliable basis for subsequent elucidation of pancreatic cancer pathogenesis. Here, SERTAD2 is linked to pancreatic adenocarcinoma.